Physician profile
Joseph Anthony Sciarrino
NPI 1225262777
$2,186.63
in general payments reported to CMS, 2019-2025
17 companies · $854 in 2025
The $854 reported for 2025 was more than what 76% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $286 · 2021: $179 · 2022: $74.16 · 2023: $16.40 · 2024: $496 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,366.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $541.68 | 2019-2024 | Xpress Loprofile |
| Genzyme Corporation | $508.54 | 2024-2025 | |
| Medtronic USA, INC. | $244.96 | 2019-2020 | |
| Optinose US, INC. | $215.73 | 2019-2025 | |
| Inspire Medical Systems, INC. | $118.69 | 2024-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $118.49 | 2024-2025 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $78.42 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $68.47 | 2025 | Tezspire |
| Spirair, INC. | $55.87 | 2025 | |
| Glaxosmithkline, LLC. | $52.11 | 2025 | Nucala |
| Smith+Nephew, INC. | $49.79 | 2024-2025 | Coblation |
| Cochlear Americas | $38.87 | 2024 | Osia Osi300 Implant, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha |
| Vertex Pharmaceuticals Incorporated | $32.68 | 2025 | |
| Phadia US INC. | $19.06 | 2024 | Immunocap |
| Alk-Abello, INC | $16.47 | 2024 | Grastek, Ragwitek, Odactra |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $13.72 | 2024 | Ryaltris |
| Novartis Pharmaceuticals Corporation | $13.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Sciarrino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.